Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-EN Version v3-EN
Language English English
Date Updated 2019-05-07 2019-04-10
Drug Identification Number 02375966 02375966
Brand name SANDOZ TELMISARTAN SANDOZ TELMISARTAN
Common or Proper name TELMISARTAN TELMISARTAN
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients TELMISARTAN TELMISARTAN
Strength(s) 80MG 80MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 500 500
ATC code C09CA C09CA
ATC description ANGIOTENSIN II ANTAGONISTS, PLAIN ANGIOTENSIN II ANTAGONISTS, PLAIN
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date
Actual start date 2018-11-05 2018-11-05
Estimated end date 2019-06-24 2019-06-03
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Sandoz not able to meet 100 pour-cent of the market demand following competition shortage situation. Limited supply availability distributed based on historical sales. Sandoz not able to meet 100 pour-cent of the market demand following competition shortage situation. Limited supply availability distributed based on historical sales.
Health Canada comments